588results about "Assay labels" patented technology

The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure is directed to methods for measuring proteomes of single cells. In one aspect, methods comprise disposing cells on a surface, synthesizing hydrogel chambers around each of the cells, lysing the cells to release intracellular proteins for adsorption onto the surface bounded by the hydrogel chambers, depolymerizing the hydrogel chambers, and quantifying the adsorbed proteins with detection antibodies to determine the single cell proteomes.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Provided herein are methods of determining a location or presence of a target analyte in a biological sample by detecting oligonucleotide-conjugated binding agents.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure relates to methods for high-throughput analysis of proteins and peptides employing a set of engineered binders that recognize terminal amino acid residues of peptide analytes. In particular, disclosed herein is the analysis of occupancy of N-linked glycosylation sites in proteins and peptides. The disclosure finds utility at large-scale profiling of N-linked glycosylation sites, as well as monitoring changes in glycosylation patterns associated with numerous disease conditions.

The present disclosure relates to the field of mass spectrometry, and particularly provides a method for determining a chemical structure of a lipid and an ion mobility-tandem mass spectrometer. The method for determining a chemical structure of a lipid includes: an ionization step of ionizing a sample to obtain sample ions; an ion mobility-based separation step of separating target lipid ions from the sample ions based on ion mobility; a first dissociation step of dissociating the target lipid ions with dissociation energy adjusted to break a first chemical bond of the target lipid ions; a mass-based selection step of selecting the target lipid ions, whose first chemical bond is broken, based on a mass number to obtain fragment ions; a second dissociation step of dissociating the fragment ions to at least break a second chemical bond of the fragment ions which has bond energy higher than the first chemical bond, to obtain diagnostic ions; and a mass analysis step of performing a mass analysis on the diagnostic ions.

The present invention provides a method for detecting two target molecules in a sample that are independent molecules and that are adjacent to or interact with each other. The method involves performing three separate assay reactions to detect a first target molecule and a second target molecule and their interactions using a proximity probe common among the three assay reactions and a nucleic acid reagent that interacts with the probe. In particular, the methods use a unique nucleic acid substrate molecule, such as a padlock probe, to detect the probes bound to their targets and determine when the probes for the two targets are in close proximity indicative of the interaction between the targets.

Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting anti-repeat-associated non-ATG (RAN) protein antibodies in a subject (e.g., a subject that has been administered a therapeutic anti-RAN protein antibody or a vaccine against a disease or disorder associated with RAN protein expression, translation, and / or accumulation, for example amyotrophic lateral sclerosis (ALS) and / or frontotemporal dementia (FTD)). In some embodiments, methods described by the disclosure comprise detecting one or more anti-RAN protein antibodies in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more target di-amino acid repeat peptides. In some embodiments, the disclosure relates to kits comprising one or more di-amino acid repeat peptides and an electrochemiluminescence-based immunoassay plate and / or reagents.

The present invention relates to methods for determining the quantity of an analyte in sample using lateral flow strips comprising highly-doped upconversion nanoparticles.

Doubly labeled water with enhanced protocol. One embodiment is a method including providing, to a user, a doubly labeled water (DLW) dose for the user to ingest, the DLW dose including deuterium and oxygen-18, wherein an amount of the deuterium is less than 0.12 grams per kilogram (g / kg) of body water of the user, and wherein an amount of the oxygen-18 is less than 0.18 g / kg of body water of the user. The method also includes receiving, from the user, a non-cooled shipment of urine samples collected in connection with ingestion of the DLW dose, wherein the urine samples remain uncooled after collection and during transit for a period of up to 24 days. The method further includes processing the urine samples with a liquid water isotope analyzer to determine one or more metabolic parameters of the user.

In a first aspect a marker (100, 404, 500) for analysing a biological sample with a plurality of target analytes (107, 113, 406, 506) is provided. The marker (100, 404, 500) comprises a first marker part (102) comprising a first affinity reagent (106, 400, 502) and a first label, the first label comprising a first polymeric backbone (108) attached to the first affinity reagent (106, 400, 502) and a plurality of first labelling moiety parts (110) attached to the first polymeric backbone (108), and a second marker part (104) comprising a second affinity reagent (112, 402, 504) and a second label, the second label comprising a second polymeric backbone (114) attached to the second affinity reagent (112, 402, 504) and a plurality of second labelling moiety parts (116) attached to the second polymeric backbone (114). The first labelling moiety parts (110) and the second labelling moiety parts (116) are configured to bind to the respective other one (110, 116) to form labelling moieties (118). The first affinity reagent and the second affinity reagent are each configured to bind specifically to one of the target analytes of the biological sample. In a further aspect, a method for analysing a biological sample is provided.

Described herein are methods for screening for a disease state. The method may include obtaining multiple data sets and identifying the disease state based on a combination of the data sets. The data sets may include biomolecule measurements obtained by multiple methods, such as through the use of particles and reference biomolecules.

Novel approaches for processing polymeric analytes, such as biopolymers, are provided herein. A method for processing a polymeric analyte may comprise coupling a monomer of the polymeric analyte to a capture moiety, cleaving the monomer from the polymeric analyte, and analyzing the cleaved monomer, e.g., using a binding agent. The methods described herein may employ the use of activating agents.

Described herein are methods and compositions for detecting an antigen using at least two antigen binders each comprising partially double-stranded nucleic acids wherein the partially double-stranded nucleic acids can template production of a linear or circular nucleic acid product.